BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy

BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy

BRAF and MEK inhibitors (BRAFi/MEKi), the standard treatment for patients with BRAFV600 mutated melanoma, are currently explored in combination with various immunotherapies, notably checkpoint inhibitors and adoptive transfer of receptor-transfected T cells. Since two BRAFi/MEKi combinations with si...

Full description

Bibliographic Details
Main Authors: Jan Dörrie, Lek Babalija, Stefanie Hoyer, Kerstin F. Gerer, Gerold Schuler, Lucie Heinzerling, Niels Schaft
Format: Article
Language:English
Published: MDPI AG 2018-01-01
Series:International Journal of Molecular Sciences
Subjects:
BRAF inhibitor
MEK inhibitor
kinase inhibitor
CAR-T cell
dabrafenib
trametinib
vemurafenib
cobimetinib
melanoma
immunotherapy
Online Access:http://www.mdpi.com/1422-0067/19/1/289

Internet

http://www.mdpi.com/1422-0067/19/1/289

Similar Items